Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Leukaemia stem cells and the evolution of cancer-stem-cell research.

Huntly BJ, Gilliland DG.

Nat Rev Cancer. 2005 Apr;5(4):311-21. Review.

PMID:
15803157
2.

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA.

Nature. 2006 Aug 17;442(7104):818-22. Epub 2006 Jul 16.

PMID:
16862118
3.

Mechanisms controlling pathogenesis and survival of leukemic stem cells.

Jordan CT, Guzman ML.

Oncogene. 2004 Sep 20;23(43):7178-87. Review.

PMID:
15378078
4.

Versatility and nuances of the architecture of haematopoiesis - Implications for the nature of leukaemia.

Brown G, Hughes PJ, Ceredig R, Michell RH.

Leuk Res. 2012 Jan;36(1):14-22. doi: 10.1016/j.leukres.2011.10.010. Epub 2011 Nov 8. Review.

PMID:
22071138
5.

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ.

Nature. 2006 May 25;441(7092):475-82. Epub 2006 Apr 5.

6.

Therapeutic implications of leukemia stem cell development.

Stubbs MC, Armstrong SA.

Clin Cancer Res. 2007 Jun 15;13(12):3439-42. Review.

7.

Concise review: Telomere biology in normal and leukemic hematopoietic stem cells.

Drummond MW, Balabanov S, Holyoake TL, Brummendorf TH.

Stem Cells. 2007 Aug;25(8):1853-61. Epub 2007 May 17. Review.

8.

Cancer stem cells and the cellular hierarchy in haematological malignancies.

Johnsen HE, Kjeldsen MK, Urup T, Fogd K, Pilgaard L, Boegsted M, Nyegaard M, Christiansen I, Bukh A, Dybkaer K.

Eur J Cancer. 2009 Sep;45 Suppl 1:194-201. doi: 10.1016/S0959-8049(09)70033-4. Review.

PMID:
19775618
9.

Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells.

Pandolfi A, Barreyro L, Steidl U.

Stem Cells Transl Med. 2013 Feb;2(2):143-50. doi: 10.5966/sctm.2012-0109. Epub 2013 Jan 24. Review.

10.

Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?

Passegué E, Jamieson CH, Ailles LE, Weissman IL.

Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11842-9. Epub 2003 Sep 22. Review.

11.

Differential destruction of stem cells: implications for targeted cancer stem cell therapy.

Sehl ME, Sinsheimer JS, Zhou H, Lange KL.

Cancer Res. 2009 Dec 15;69(24):9481-9. doi: 10.1158/0008-5472.CAN-09-2070.

12.

[Cancer stem cells in the haematopoietic system].

Urup T, Madsen G, Hallager S, Schmitz A, Fogd K, Bøgsted M, Nyegaard M, Sørensen KD, Johnsen HE.

Ugeskr Laeger. 2010 Sep 20;172(38):2597-600. Danish.

PMID:
20920402
13.

CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.

Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z, Valk P, Ossenkoppele G, Zeijlemaker W, Kaspers G, Cloos J, Schuurhuis GJ.

Br J Haematol. 2016 Apr;173(2):219-35. doi: 10.1111/bjh.13941. Epub 2016 Jan 27.

PMID:
26814163
14.

Pathways involved in the evolution of leukemic stem cells.

Zhang PY, Yang YJ, Fu CM, Xiang LL, Wang Q, Li XL.

Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1356-63. Review.

15.

The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.

Hoang VT, Buss EC, Wang W, Hoffmann I, Raffel S, Zepeda-Moreno A, Baran N, Wuchter P, Eckstein V, Trumpp A, Jauch A, Ho AD, Lutz C.

Int J Cancer. 2015 Aug 1;137(3):525-36. doi: 10.1002/ijc.29410. Epub 2015 Jan 14.

16.

[Leukemia stem cells and their targeted clearance].

Liu B, Shi C, Zhou J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Aug;22(4):1120-3. doi: 10.7534/j.issn.1009-2137.2014.04.044. Review. Chinese.

PMID:
25130840
17.

Role of microRNAs in leukemia stem cells.

Huang J, Mo YY.

Front Biosci (Schol Ed). 2012 Jan 1;4:799-809. Review.

PMID:
22202091
18.

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.

Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5009-14. doi: 10.1073/pnas.1100551108. Epub 2011 Mar 7.

19.

Xenograft models for normal and malignant stem cells.

Goyama S, Wunderlich M, Mulloy JC.

Blood. 2015 Apr 23;125(17):2630-40. doi: 10.1182/blood-2014-11-570218. Epub 2015 Mar 11. Review.

20.

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L.

PLoS One. 2013 Nov 11;8(11):e78897. doi: 10.1371/journal.pone.0078897. eCollection 2013.

Supplemental Content

Support Center